Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

Clinical trial NCT02345252 · COMPLETED

Trial details

NCT number: NCT02345252
Sponsor: Gilead Sciences
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HIV-1 Infection

Start date: 2015-01-26
Primary completion: 2016-06-22
Enrollment: 632

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.